![](http://www.yuhua99.com/CompanyDynamic/2025-2/Raw/b025c82a-c65d-41d3-ab13-f706643288d2.jpeg)
開工大吉!懷揣著憧憬和希望,佰樂博生物攜手與您展開新一年的宏圖,愿我們繼續(xù)凌風(fēng)破浪,再登峰境。
新春伊始,佰樂博生物代理的AntibodySystem就收錄了5篇引用產(chǎn)品的文獻(xiàn),用滿滿的實(shí)力與正能量展示新年新氣象!
01
![](http://www.yuhua99.com/CompanyDynamic/2025-2/Raw/fd6c6334-c115-42cf-ad55-82ebdb203fb6.png)
TarIKGC: A Target Identification Tool Using Semantics-Enhanced Knowledge Graph Completion with Application to CDK2 Inhibitor Discovery
Journal of Medicinal Chemistry. Vol 68/Issue 2Article.
Recombinant human CDK2 (with N-His) protein
02
![](http://www.yuhua99.com/CompanyDynamic/2025-2/Raw/133c0109-7183-42f5-8e2e-f08f3f135dfe.png)
TarIKGC: A Target Identification Tool Using Semantics-Enhanced Knowledge Graph Completion with Application to CDK2 Inhibitor Discovery
Journal of Medicinal Chemistry. Vol 68/Issue 2Article.
Recombinant human CDK2 (with N-His) protein
03
![](http://www.yuhua99.com/CompanyDynamic/2025-2/Raw/3118aacc-4b8d-474b-ac1c-45e5e9e9843f.png)
TarIKGC: A Target Identification Tool Using Semantics-Enhanced Knowledge Graph Completion with Application to CDK2 Inhibitor Discovery
Journal of Medicinal Chemistry. Vol 68/Issue 2Article.
Recombinant human CDK2 (with N-His) protein
04
![](http://www.yuhua99.com/CompanyDynamic/2025-2/Raw/76dc0599-9db4-4a10-8617-e69fa47d2dea.png)
Linoleic acid promotes TF expression through PPAR-α, which leads to tumor progression in primary pulmonary lymphoepithelioma-like carcinoma
Research Square. ?posted 10 Jan, 2025
Recombinant human CDK2 (with N-His) protein
05![](http://www.yuhua99.com/CompanyDynamic/2025-2/Raw/d5ffb169-13da-4888-b870-229f182367b6.png)
Development of a genetically modified full-length human respiratory syncytial virus preF protein vaccine
Research Grade NirsevimabAnti-HRSV F/Fusion glycoprotein F0 Antibody (Am14)??
Anti-HRSV-A F/Fusion glycoprotein F0 Antibody (D25)?
Anti-HRSV F/Fusion glycoprotein F0 Antibody (Am14)?
再續(xù)華章
AntibodySystem多年來與全球多所知名高校和科研機(jī)構(gòu)深入合作,合作單位包括清華大學(xué)、北京大學(xué)、復(fù)旦大學(xué)、悉尼大學(xué)、麻省理工學(xué)院、東京大學(xué)和紐約大學(xué)等世界頂尖學(xué)術(shù)機(jī)構(gòu)。研究領(lǐng)域涵蓋廣泛,涉及病毒學(xué)與疫苗研究、腫瘤研究、自身免疫疾病、神經(jīng)科學(xué)與退行性疾病、抗體藥物與細(xì)胞治療、細(xì)菌寄生蟲研究以及過敏反應(yīng)等多個(gè)生命科學(xué)領(lǐng)域。
截至目前,引用佰樂博生物代理AntibodySystem產(chǎn)品的文獻(xiàn)已累計(jì)達(dá)到200余篇,發(fā)表在Nature、Cell、Immunity、Molecular Cancer 等頂級期刊的文獻(xiàn)共有43篇。
作為AntibodySystem等多個(gè)國際頂尖品牌在亞洲區(qū)的獨(dú)家代理商,佰樂博生物將繼續(xù)秉持“專業(yè)、專注、專心”的理念,致力為生命科學(xué)領(lǐng)域的科研人員提供高質(zhì)量的科研試劑與技術(shù)服務(wù),助力科研進(jìn)步,支持生命科學(xué)領(lǐng)域的前沿探索。
值此新歲啟封,萬物復(fù)蘇的開工吉日里,佰樂博生物真心祝愿各位老師在新的一年里,科研成果滿滿,文獻(xiàn)發(fā)到手軟!
為了感謝廣大科研工作者對AntibodySystem SAS的支持與信任,佰樂博和AntibodySystem SAS聯(lián)合推出2025年度文獻(xiàn)引用獎(jiǎng)勵(lì)活動(dòng)。凡在SCI期刊上發(fā)表文章并使用AntibodySystem SAS全線產(chǎn)品的科研工作者,均可申請獎(jiǎng)勵(lì),具體活動(dòng)詳情可點(diǎn)擊下方圖片了解。
![](http://www.yuhua99.com/CompanyDynamic/2025-2/Raw/1ccd5f5f-efc5-4317-9be4-082faabc3660.jpeg)